{"image_url":null,"type":"rich","url":"https://monnalisasmile.hatenablog.com/entry/2023/03/09/024952","categories":["MBA","MIT","SFMBA","finance","technology"],"published":"2023-03-09 02:49:52","provider_url":"https://hatena.blog","author_name":"monnalisasmile","blog_url":"https://monnalisasmile.hatenablog.com/","author_url":"https://blog.hatena.ne.jp/monnalisasmile/","title":"Day 120 in MIT Sloan Fellows Class 2023, M&A and PE 5 \"Squeeze out\"","height":"190","blog_title":"\u8db3\u308b\u3053\u3068\u3092\u77e5\u3089\u305a","description":"Roche and Genentech case www.hbs.edu Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros \u2026","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fmonnalisasmile.hatenablog.com%2Fentry%2F2023%2F03%2F09%2F024952\" title=\"Day 120 in MIT Sloan Fellows Class 2023, M&amp;A and PE 5 &quot;Squeeze out&quot; - \u8db3\u308b\u3053\u3068\u3092\u77e5\u3089\u305a\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","provider_name":"Hatena Blog","width":"100%","version":"1.0"}